Novel strategies and therapeutics for the treatment of prostate carcinoma Journal Article
| Authors: | Morris, M. J.; Scher, H. I. |
| Article Title: | Novel strategies and therapeutics for the treatment of prostate carcinoma |
| Abstract: | BACKGROUND. An increased understanding of the biology of prostate carcinoma has led to the clinical evaluation of mechanism-based and targeted therapies. Modulating the immune system has been pursued through the use of both active and passive immunity as well as the ex vivo genetic manipulation of effector cells. A variety of gene therapies has been proposed not only to replace defective genes but to localize activation of prodrugs. Angiogenesis and tumor invasion also have been targeted, as have cell cycling and signal transduction. Strategies promoting apoptosis and augmenting differentiation are also under study. METHODS. This study is a review of current clinical strategies using biologic, immunologic, and genetic approaches for the treatment of prostate carcinoma. RESULTS. The clinical development of therapy targeting differentiation, apoptosis, cell signaling, angiogenesis, metastasis, immune surveillance, and others are in various stages of clinical development. A disease states model is used to discuss treatment groups, outcome measures, and other trial design elements in relation to specific therapeutic strategies. CONCLUSIONS. Development of novel agents requires consideration of where in the natural history of the disease they should be applied. In addition, understanding the genetic and molecular alterations that occur as the disease progresses from a localized to a metastatic state, and from androgen dependence to independence, is necessary. Clinical trial design will require consideration of cytostatic and cytotoxic effects, the status of pathways not directly targeted, and potentially unexpected influences on prostate specific antigen expression by these agents. (C) 2000 American Cancer Society. |
| Keywords: | signal transduction; epidermal growth factor; vasculotropin; cancer chemotherapy; unclassified drug; androgen; thalidomide; angiogenesis inhibitor; cisplatin; nonhuman; antineoplastic agents; antigen expression; prostate specific antigen; animals; cell cycle; interleukin 2; protein bcl 2; cancer immunotherapy; apoptosis; granulocyte macrophage colony stimulating factor; calcitriol; cytotoxicity; angiogenesis; protein p53; genetic manipulation; cancer resistance; cancer invasion; prostatic neoplasms; cytokine; immunotherapy; gamma interferon; protein farnesyltransferase inhibitor; gene therapy; biologic therapy; effector cell; immunosurveillance; angiogenesis inhibitors; antibody; retinoid; clinical trials; marimastat; arylbutyric acid derivative; prostate carcinoma; cytostasis; fumagillol chloroacetylcarbamate; prinomastat; oncogene neu; active immunization; passive immunization; endostatin; phenylacetic acid; 4 dedimethylaminosancycline; hormone dependence; antineoplastic therapy; squalamine; humans; human; male; priority journal; article; peroxisome proliferator activated receptor; monoclonal antibody cc49; ptk 787 zk |
| Journal Title: | Cancer |
| Volume: | 89 |
| Issue: | 6 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2000-09-15 |
| Start Page: | 1329 |
| End Page: | 1348 |
| Language: | English |
| DOI: | 10.1002/1097-0142(20000915)89:6<1329::aid-cncr19>3.0.co;2-q |
| PUBMED: | 11002230 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 18 November 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work